New hope for hard-to-treat lung cancer: combo therapy enters phase 2 trial

NCT ID NCT07306624

Recruiting now Disease control Sponsor: STCube, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 23, 2026 · Updated 25 times

Summary

This study tests whether adding nelmastobart to the chemotherapy drug docetaxel can help people with advanced non-small cell lung cancer whose cancer has stopped responding to or cannot tolerate standard platinum-based chemo or immunotherapy. About 62 adults with a specific marker (BTN1A1 TPS score ≥50) will receive the combination. The main goal is to see if the treatment delays cancer growth or improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kangbuk Samsung Hospital
RECRUITING

Seoul, South Korea

Contact
Korea University Anam Hospital
NOT_YET_RECRUITING

Seoul, South Korea

Contact
Samsung Medical Center
RECRUITING

Seoul, South Korea

Contact
Seoul National University Bundang Hospital
NOT_YET_RECRUITING

Seoul, South Korea

Contact
The Catholic University of Korea St. Vincent's Hospital
NOT_YET_RECRUITING

Gyeonggi-do, South Korea

Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER